22. Gao J.V., You S., Liu Z.Y., et al. Different metabolic phenotypes of obesity and risk of coronary artery calcium progression and incident cardiovascular disease events: the CARDIA study. Arterioscler Thromb Vasc Biol. 2022; 42 (5): 677–88. DOI: https://doi.org/10.1161/ATVBAHA.122.317526
23. Rotar O., Boyarinova M., Orlov A., et al. Metabolically healthy obese and metabolically unhealthy non-obese phenotypes in a Russian population. Eur J Epidemiol. 2017; 32 (3): 251–4. DOI: https://doi.org/10.1007/s10654-016-0221-z; PMID: 28039558.
24. Mustafina S.V., Vinter D.A., Shcherbakova L.V., et al. Gender and age-related features of metabolically healthy obesity phenotype prevalence. Byulleten’ sibirskoy meditsiny [Bulletin of Siberian Medicine]. 2020; 19 (1): 76–84. URL: https://cyberleninka.ru/article/n/ (in Russian) (date of access June 22, 2023).
25. Vinter D.A., Mustafina S.V., Rymar O.D., et al. Behavioral and social risk factors for metabolically unhealthy obesity: data form a 12-year prospective study in the Russian population. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2022; 27 (5). URL: https://cyberleninka.ru/article/n/ (in Russian) (date of access June 22, 2023).
26. Liu J., Zhang Y., Lavie C.J., Moran A.E. Trends in metabolic phenotypes according to body Mass Index Among US adults, 1999–2018. Mayo Clin Proc. 2022; 97 (9): 1664–79. DOI: https://doi.org/10.1016/j.mayocp.2022.02.013; PMID: 35691704.
27. Wang J.S., Xia P.F., Ma M.N., et al. Trends in the prevalence of metabolically healthy obesity among US adults, 1999–2018. JAMA Netw Open. 2023; 6 (3): e232145. DOI: https://doi.org/10.1001/jamanetworkopen.2023.2145 PMID: 36892842; PMCID: PMC 9999245.
28. Blüher M. Metabolically healthy obesity. Endocr Rev. 2020; 41 (3): bnaa004. DOI: https://doi.org/10.1210/endrev/bnaa004 PMID: 32128581; PMCID: PMC 7098708.
29. Smith G.I., Mittendorfer B., Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019; 129 (10): 3978–89. DOI: https://doi.org/10.1172/JCI129186 PMID: 31524630; PMCID: PMC 6763224.
30. Tsatsoulis A., Paschou S.A. Metabolically healthy obesity: criteria, epidemiology, controversies, and consequences. Curr Obes Rep. 2020; 9 (2): 109–20. DOI: https://doi.org/10.1007/s13679-020-00375-0 PMID: 32301039.
31. Mongraw-Chaffin M., Foster M.C., Anderson C.A.M., et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2018; 71 (17): 1857–65. DOI: https://doi.org/10.1016/j.jacc.2018.02.055 PMID: 29699611; PMCID: PMC 6002856.
32. Eckel N., Li Y., Kuxhaus O., et al. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30-year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018; 6 (9): 714–24. DOI: https://doi.org/10.1016/S2213-8587(18)30137-2; PMID: 29859908.
33. Morkedal B., Vatten L.J., Romundstad P.R., et al. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trondelag Health Study), Norway. J Am Coll Cardiol. 2014; 63 (11): 1071–8. DOI: https://doi.org/10.1016/j.jacc.2013.11.035; PMID: 24345592.
34. Caleyachetty R.M.B.B., Thomas G.N., Toulis K.A., et al. Metabolically healthy obese and incident cardiovascular disease events among 3,5 million men and women. J Am Coll Cardiol. 2017; 70 (12): 1429–37. DOI: https://doi.org/10.1016/j.jacc.2017.07.763
35. Iacobellis G., Sharma A.M. Obesity and the heart: redefinition of the relationship. Obes Rev. 2007; 8 (1): 35–9. DOI: https://doi.org/10.1111/j.1467-789X.2006.00257.x PMID: 17212794.
36. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022; 19: 593–606. DOI: https://doi.org/10.1038/s41569-022-00679-9
37. Romero-Corral A., Montori V.M., Somers V.K., et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006; 368 (9536): 666–78. DOI: https://doi.org/10.1016/S0140-6736(06)69251-9 PMID: 16920472.
38. Khadir A., Kavalakatt S., Madhu D., et al. Spexin as an indicator of beneficial effects of exercise in human obesity and diabetes. Sci Rep. 2020; 10 (1): 10635. DOI: https://doi.org/10.1038/s41598-020-67624-z PMID: 32606431; PMCID: PMC 7327065.
39. Corres P., Fryer S.M., Aguirre-Betolaza A.M., et al. A metabolically healthy profile is a transient stage when exercise and diet are not supervised: long-term effects in the EXERDIET-HTA study. Int J Environ Res Public Health. 2020; 17 (8): 2830. DOI: https://doi.org/10.3390/ijerph17082830 PMID: 32326133; PMCID: PMC 7216152.
40. Laforest S., Michaud A., Paris G., et al. Comparative analysis of three human adipocyte size measurement methods and their relevance for cardiometabolic risk. Obesity (Silver Spring). 2017; 25 (1): 122–31. DOI: https://doi.org/10.1002/oby.21697
41. Ler P., Li X., Hassing L.B., et al. Independent and joint effects of body mass index and metabolic health in mid- and late-life on all-cause mortality: a cohort study from the Swedish Twin Registry with a mean follow-up of 13 years. BMC Public Health. 2022; 22: 718. DOI: https://doi.org/10.1186/s12889-022-13082-3
42. Putra I.C.S., Kamarullah W., Prameswari H.S., et al. Metabolically unhealthy phenotype in normal weight population and risk of mortality and major adverse cardiac events: a meta-analysis of 41 prospective cohort studies. Diabetes Metab Syndr. 2022; 16 (10): 102635. DOI: https://doi.org/10.1016/j.dsx.2022.102635; PMID: 36240685.
43. Nolan C.J., Ruderman N.B., Kahn S.E., et al. Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes. 2015; 64 (3): 673–86. DOI: https://doi.org/10.2337/db14-0694 PMID: 25713189; PMCID: PMC 4338588.
44. De Lorenzo A., Soldati L., Sarlo F., et al. New obesity classification criteria as a tool for bariatric surgery indication. World J Gastroenterol. 2016; 22 (2): 681–703. DOI: https://doi.org/10.3748/wjg.v22.i2.681 PMID: 26811617; PMCID: PMC 4716069.
45. Hashemipour S., Esmailzadehha N., Hamid H., et al. Association of metabolic syndrome components with insulin resistance in normal weight population: the Qazvin Metabolic Diseases study. J Endocrinol Invest. 2015; 38 (10): 1111–5. DOI: https://doi.org/10.1007/s40618-015-0302-y; PMID: 25952300.
46. Xu X., Bhagavathula A.S., Zhang Y., et al. Sex differences in the TyG index and cardiovascular risk factors in metabolically obese normal weight phenotype. Int J Endocrinol. 2022; 2022: 1139045. DOI: https://doi.org/10.1155/2022/1139045 PMID: 35371258; PMCID: PMC 8970881.
47. De Lorenzo A., Martinoli R., Vaia F., Di Renzo L. Normal weight obese (NWO) women: an evaluation of a candidate new syndrome. Nutr Metab Cardiovasc Dis. 2006; 16 (8): 513–23. DOI: https://doi.org/10.1016/j.numecd.2005.10.010; PMID: 17126766.
48. Cruz-Jentoft A.J., Bahat G., Bauer J., et al.; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48 (1): 16–31. DOI: https://doi.org/10.1093/ageing/afy169 PMID: 30312372; PMCID: PMC 6322506.
49. Liu C., Cheng K.Y., Tong X., et al. The role of obesity in sarcopenia and the optimal body composition to prevent against sarcopenia and obesity. Front Endocrinol (Lausanne). 2023; 14: 1077255. DOI: https://doi.org/10.3389/fendo.2023.1077255 PMID: 36936175; PMCID: PMC 10016224.
50. Batsis J.A., Villareal D.T. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018; 14 (9): 513–37. DOI: https://doi.org/10.1038/s41574-018-0062-9 PMID: 30065268; PMCID: PMC 6241236.
51. Brown R.J., Araujo-Vilar D., Cheung P.T., et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016; 101 (12): 4500–11. DOI: https://doi.org/10.1210/jc.2016-2466; PMID: 27710244; PMCID: PMC 5155679.